OINDPnews


H&T Presspart banner

Business

Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray

According to Pneumagen, the company has closed a £3.8 million funding round led by Thairm Bio and Scottish Enterprise, with proceeds intended to fund GMP manufacturing and Phase 2 development of its Neumifil carbohydrate binding module (mCBM) nasal spray for the prevention of respiratory viruses. Pneumagen initiated a Phase 1 study of Neumifil in November 2021 and … [Read more...] about Pneumagen raises £3.8 million for Phase 2 development and manufacturing of Neumifil antiviral nasal spray

CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF

The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics for development of the company's Feldan Shuttle technology for pulmonary delivery of drugs to treat cystic fibrosis. Neither the company nor the CFF disclosed the amount of the award, which was made under the CFF's Path to a Cure initiative. Social media posts from the CFF said that the purpose … [Read more...] about CFF awards grant to Feldan Therapeutics for development of pulmonary delivery technology for CF

Medlab Clinical gets grant from NSW government for intranasal RNA vaccine against COVID-19

Australian biotech Medlab Clinical said that it has received a grant from the New South Wales government for development of a proof-of-concept intranasal vaccine based on its NanoCelle "sub-micron delivery platform" technology. The company added that it will develop the vaccine in partnership with OINDP specialist Daniela Traini of the Woolcock Institute of Medical … [Read more...] about Medlab Clinical gets grant from NSW government for intranasal RNA vaccine against COVID-19

Poolbeg Pharma licenses intranasal antiviral from the University of Warwick

Open Orphan spin-out Poolbeg Pharma said that it has acquired an exclusive license for an intranasal RNA-based immunotherapy for the prevention and treatment of viral respiratory infections from the University of Warwick. According to the company, in vivo studies have demonstrated that the antiviral, which Poolbeg is calling POLB 002, has the potential to be effective … [Read more...] about Poolbeg Pharma licenses intranasal antiviral from the University of Warwick

Covis to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada

Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in Canada. In November 2021, Covis announced that it had acquired global rights to market … [Read more...] about Covis to distribute Seebri Breezhaler and Ultibro Breezhaler in Canada

Pfizer gets ex-US rights to Biohaven’s zavegepant nasal spray

Pfizer is paying Biohaven Pharmaceutical a total of $500 million upfront plus up to $740 million in potential milestone payments for the rights to market Biohaven's rimegepant (Nurtec ODT) and zavegepant (BHV-3500) outside of the US. Rimegepant is an oral drug approved in the US and several other countries for the prevention and treatment of migraine; zavegepant is a … [Read more...] about Pfizer gets ex-US rights to Biohaven’s zavegepant nasal spray

Ritedose launches budesonide inhalation suspension in US, gets FDA approval for albuterol inhalation solution

US-based Ritedose Pharmaceuticals, a subsidiary of CDMO Ritedose Corporation, has announced the launch of generic unit dose budesonide inhalation suspension (0.5 mg/2 ml) packaged for use in hospitals. Also, at the end of December, the FDA approved the company's ANDA for two strengths of albuterol inhalation solution, generic equivalents of Mylan's Accuneb. … [Read more...] about Ritedose launches budesonide inhalation suspension in US, gets FDA approval for albuterol inhalation solution

Only one patent remains in contention in the United Therapeutics effort to delay final FDA approval of Liquidia’s Yutrepia treprostinil DPI

According to Liquidia Corporation, United Therapeutics has agreed to a court judgment finding that Liquidia did not infringe United Therapeutic's US Patent No. 9,604,901. In October 2021, an inter partes review by the US Patent Trial and Appeal Board (PTAB) determined that 7 of the 9 claims in that patent were invalid. United Therapeutics initially filed suit … [Read more...] about Only one patent remains in contention in the United Therapeutics effort to delay final FDA approval of Liquidia’s Yutrepia treprostinil DPI

EnBiotix raises $11 million in financing round led by Vectura for further development of ColiFin, murepavidin

EnBiotix, which is in the process of merging with inhaled murepavadin developer Polyphor, announced that it has raised $11 million in a financing round led by inhaled drug CDMO Vectura. Sanford Biosciences and the Cystic Fibrosis Foundation (CFF) also contributed to the financing, which will fund further development of ColiFin nebulized colistimethate sodium in … [Read more...] about EnBiotix raises $11 million in financing round led by Vectura for further development of ColiFin, murepavidin